Dhiran Verghese
Chicago, ILNPI 1942787064
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 89 payments — averaging $63.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$651
- Medtronic$535
- Boston Scientific$400
- E.r. Squibb & Sons, L.L.C.$322
- Shockwave Medical, Inc$306
- plus $2K from 15 others
What the payments were for
- Food & beverage$5,45396%
- Education$2214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 15 | $1,112 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $651 |
| Medtronic | 3 | $535 |
| Boston Scientific | 8 | $400 |
| E.r. Squibb & Sons, L.L.C. | 3 | $322 |
| Shockwave Medical, Inc | 2 | $306 |
| Inari Medical, Inc. | 2 | $306 |
| Pfizer | 12 | $300 |
| Lexicon Pharmaceuticals, Inc. | 5 | $292 |
| Vital Connect, Inc | 1 | $200 |
| Alnylam Pharmaceuticals Inc. | 3 | $172 |
| Abbott | 3 | $168 |
| Penumbra, Inc. | 1 | $143 |
| AstraZeneca | 3 | $143 |
| Edwards Lifesciences | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $116 |
| Cardiva Medical, Inc. | 1 | $114 |
| Astellas Pharma US Inc | 1 | $105 |
| Boehringer Ingelheim | 1 | $101 |
| Cvrx, Inc. | 3 | $42 |
| Terumo Medical Corporation | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$376
- COBALT DR MRI SURESCAN$314
- LifeVest$309
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$306
- FLOWTRIEVER CATHETER, S$246
- CT THROMBECTOMY SYSTEM KIT$246
- RESOLUTE ONYX$221
- VITALPATCH RTM$200
- Indigo System$143
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- AMVUTTRA$125
- EVKEEZA$116
- Cardiva VASCADE 6/7F VCS$114
- Inpefa$114
- ELIQUIS$113
- MitraClip$111
- CAMZYOS$110
- JARDIANCE$101
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 18 | $531,962 |
| JardianceEmpagliflozin | 107 | $90,101 |
| EntrestoSacubitril/Valsartan | 54 | $47,129 |
| EliquisApixaban | 28 | $17,245 |
| Metoprolol Succinate | 45 | $379 |
| Carvedilol | 14 | $158 |
| Spironolactone | 28 | $139 |
| Furosemide | 17 | $108 |
| Losartan Potassium | 17 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $300 | $549,20746 claims |
| Boehringer IngelheimJardiance | $101 | $90,101107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Illinoison file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.